Get started
JetEquities

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxi

Long
Atossa Therapeutics, Inc. (NASDAQ:ATOS)  
JetEquities  
NASDAQ:ATOS   Atossa Therapeutics, Inc.
Beyond Technical Analysis
3
0
beyondta
ATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.